The laboratory of Michael Caligiuri, MD, began in 1990 at Roswell Park Cancer Institute (RPCI) when Dr. Caligiuri was a newly appointed assistant professor in Internal Medicine (Oncology) and Microbiology/Immunology at RPCI and the State University of New York (SUNY) at Buffalo.
The Caligiuri laboratory moved to The Ohio State University (OSU) in
July of 1997. Fifteen members of Dr. Caligiuri's team at RPCI joined him
at OSU, and since that time he has recruited additional
members into the laboratory. The laboratory consists of investigators at the technical, undergraduate, graduate,
postgraduate, and assistant professor level. The entire laboratory is
supervised by Ms. Donna Bucci . The Caligiuri laboratory is also the
home for one of the world's largest leukemia tissue banks, the Cancer
and Leukemia Group B (CALGB) Leukemia Tissue Bank.
Dr. Caligiuri's laboratory has evolved to investigate three main scientific areas:
First is to understand the development and normal role of the body's large granular lymphocytes called natural killer cells , and to exploit their properties in order to develop effective therapies against cancer and immune deficiency.
The second is to understand why organ transplant patients with iatrogenic immune deficiency are highly susceptible to the development of lymphoma associated with the Epstein-Barr virus and to develop a preventative strategy for this disorder. We use a SCID-human mouse model to explore novel therapies for the treatment of this and other types of lymphoma.
The third area of focus is the molecular basis for the development of acute leukemia . We have mouse models of leukemia as well as the world's largest bank of frozen human leukemia cells to study the pathogenesis of acute leukemia, the prognostic significance of molecular defects in acute leukemia, and novel therapies for acute leukemia.